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The recombinant vaccinia–rabies vaccine, now known as Raboral®, has been widely used in Europe and North America to control/eliminate rabies in the principal wildlife vectors, and thus prevent human transmission. The origins of this vaccine are sometimes forgotten, although the formulation has not changed substantially in almost four decades. This groundbreaking vaccine was assembled by a team at a very young (at that time) genetic engineering company, Transgène, in Strasbourg, France. The joint leaders of the rabies vaccine team reflect, 36 years later, on the trials and tribulations that went hand in hand with the construction of the vaccine.


Rabies is a devastating disease that is inexorably fatal, unless – as Louis Pasteur demonstrated [1] – it is rapidly treated by immunization. Even so, the vaccination regimen that Pasteur recommended is punishing, and brought its own risks of hyperinflammation. In the mid-20th century rabies was widespread among wildlife (principally foxes in Europe and raccoons in North America), and even in developed countries the bite of an infected animal was a death warrant if not immediately and intensively treated.

With the advent of genetic engineering (GE) technologies in the 1980s, the renowned Institut Mérieux in Lyon, France – established in 1897 by Marcel Mérieux, one of Louis Pasteur's assistants – brought a new task to the newly established GE company Transgène in Strasbourg: make a rabies vaccine. This chore was handed down to ourselves, two young postdoctoral scientists in the company.

Transgène, founded by Pierre Chambon and Philippe Kourilsky in 1979/1980, although being allocated half a floor in Pierre Chambon's institute at the University of Strasbourg (Figure 1), was not quite ready: all available resources, at the very beginning, were allocated to setting up all the essential GE ingredients – oligonucleotide synthesis, DNA sequencing (done manually on thin polyacrylamide gels using radiophosphorus), basic sequence analysis, simple expression vectors in bacteria, yeast, and mammalian cells, even making our own restriction enzymes. Other GE companies were well ahead, and had cloned and expressed key molecules such as growth hormone, interferons, and hepatitis B surface antigen. We were both over-optimistic and underweight.

Construction of the Vaccine

But we set to. The Scientific Director of Transgène, Jean-Pierre Lecocq, established a collaboration with researchers at the Wistar Institute (Figure 1) under Hilary Koprowski (Philadelphia) who had obtained, for the first time, a cDNA copy of rabies virus glycoprotein at the end of 1981 [2, 3] – the key antigenic determinant of this virus. Beginning in early 1982, we expressed the cDNA in E. coli, B. subtilis, yeast, mammalian cells (reviewed in [4]). The pressure was on, we worked 7 days a week, so did our key technical staff; we were fuelled by Martha Argerich interpreting J.S. Bach on the tape player until long after the sun set over the Vosges hills (Box 1). The extracts were sent to the rabies expert in Philadelphia, Tadeusz Wiktor. He systematically vaccinated lab animals (mostly mice and hamsters) with the extracts, and then challenged them with street rabies virus. None survived.

We were dismayed, and ready to give up. Two developments changed everything. First, at a chance meeting with Peter Curtis (Wistar) he advised that there was a possible problem with his cDNA sequence – there appeared to be a mutation. Second, we were impressed by the growing achievements of recombinant vaccinia virus (the basis of the smallpox vaccine), inspired by Enzo Paoletti in 1983 [5], in eliciting immunity beyond what could be obtained with bacteria, yeasts, or even mammalian cells.

The mutation in the rabies glycoprotein cDNA was indeed suspect – a Pro to Leu mutation near the beginning of the mature protein sequence at a position that (to our minds) seemed to resemble known mutations at the beginning of the oncoprotein RAS (Gly to Asp, or Gly to Val) that entirely transform the structure and activity of the protein. The first thing we did was to correct the mutation. Something we had never done before, and this took months. In the key Nature paper the reader will see that, because our techniques were challenged, we took advantage of an artificial site for Dam methylase (that governs mismatch repair in E. coli) site to tip the balance in our favor (unheard of today) (Figure 2A). But it worked! We wonder how many rabies glycoprotein sequences circulating in the GE world today bear that same signature alteration.

The second thing we did was to get vaccinia up and running as a vehicle. We got into collaboration with Robert Drillien and Danièle Spehner at the Institut de Virologie on the same campus, and they supplied us with a microgram of vaccinia virus DNA. The key thymidine kinase gene – required for recombinational exchange with the vaccinia genome – had already been cloned by Robert, but we lacked a promoter to drive expression. We wanted the 7.5K gene promoter, that had been worked up by researchers in the USA, but starting with only 1 microgram of DNA (the vaccinia genome is ~190 kb in length), given the state of the technology, cloning was near to impossible. In the event we turned to calculations of insert size, vector size, and absolute concentrations based on the physicochemistry of ligation [6, 7], and brewed up an optimum ligase mix. Only four clones were obtained. Two were 7.5K in one orientation, and two were the same promoter in the other orientation! Were we lucky? No, in retrospect we would have got nothing had we not used the mathematics of the ligation reaction to get what we needed. 

From there it moved quite rapidly. Ligate the promoter to the modified rabies G coding sequence, insert the construct into the vaccinia TK gene on a plasmid – then transfect the recombinant (TK-negative) plasmid into vaccinia virus-infected cells, and select chemically using bromodeoxyuridine (that kills TK-positive viruses). And we had our first vaccinia–rabies recombinant ('26D3').

This sped off to Tad Wiktor in Philadelphia. We waited what seems like an eternity, but he reported quickly back with his preliminary results: 'this is the best rabies vaccine I have ever seen' – it protected mice against severe rabies challenge (Figure 2B–D) better than any other rabies vaccine. And so it turned out – first published in September 1984 ([8, 9]; reviewed in [10-12]).





The vaccine was originally envisaged for human use, and steps were taken in this direction in collaboration with the Institut Mérieux. However, there was reluctance to introduce a new vaccinia-based vaccine for human use because smallpox, the original target of vaccinia, had recently been declared eradicated by the World Health Organization (WHO) [13]. A committee of international experts including WHO representatives, who met in Bethesda, MD, in November 1984, did not envisage early human use [14]. However, because rabies is transmitted to humans principally from domestic dogs – that themselves acquire the infection from foxes (in Europe), and from raccoons and coyotes (in North America) – the next step was to try the new vaccine out for efficacy in animals. With support from Philippe Desmettre at the Institut Mérieux, Transgène was in touch with Pierre-Paul Pastoret in Belgium and colleagues at the French Ministry of Agriculture Rabies Research Station in Malzéville close to Nancy, and this was soon followed by the demonstration that oral administration of the vaccine (108 pfu) to foxes (Figure 4) gave complete protection against lethal challenge, and almost complete protection following administration in home-made bait [15], quickly followed by oral protection of raccoons in the USA by colleagues at the Wistar Institute [16].

This was expanded to small-trials followed by large-scale campaigns to eradicate sylvatic rabies in Europe and North America by dropping baits (e.g., chicken heads or artificial baits) seeded with live recombinant virus from helicopters (Figure 3B) according to a carefully planned routine (taking in mind the number of wildlife species per square kilometer, and the transmission factor R – what percentage of animals do we need to vaccinate to block propagation? – of current interest given the COVID pandemic). It worked. The first trials (Figure 5) demonstrated wide uptake by foxes and downturn of rabies cases. Using this vaccine, rabies has now been widely eliminated in many European countries; substantial reductions in rates of rabies in wildlife have been achieved in several areas of Eastern USA and Canada (Table 1) where active vaccination campaigns are ongoing (http://www.raboral.com/about-rabies/raboral-v-rg). Over 250 million doses of Raboral® have been distributed worldwide [17]. Although highly successful in Europe [18], campaigns in the USA and Canada are constrained because of rabies re-emergence through long-distance movements of carrier species such as arctic foxes [17].

Vaccinia-Based Vaccines for Human Use

The vaccina–rabies recombinant has never been approved for human use, even though vaccinia virus has been used widely across the world in our populations to eradicate smallpox, and the vaccinia–rabies recombinant is very much attenuated compared to standard strains of vaccinia. Notwithstanding, intense efforts have been made to develop vaccinia as an anticancer agent for direct prophylactic or curative use in human [19-22], but for recombinants expressing viral antigens few clinical trials have been carried out (with some exceptions; e.g., [23]). Efforts in the 1990s were invested into the development of viral vectors based on vaccinia derivatives such as modified virus Ankara (MVA) [24], or fowlpox or canarypox [25]. More recently, high levels of protective antibodies have been obtained against SARS coronavirus using vaccinia recombinants in experimental animals (e.g., [26-28]), and, given the threat of COVID-19, MVA-based recombinants are being actively explored in California [29] and Germany (https://www.vfa.de/de/englische-inhalte/vaccines-to-protect-against-covid-19) as potential vaccines against SARS-COV-2, the etiologic agent of COVID-19. 
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